Copaxone and Stress and anxiety - a phase IV clinical study of FDA data
Stress and anxiety is found among people who take Copaxone, especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Copaxone and have Stress and anxiety. It is created by eHealthMe based on reports of 53,633 people who have side effects when taking Copaxone from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
53,633 people reported to have side effects when taking Copaxone.
Among them, 1,206 people (2.25%) have Stress and anxiety.
What is Copaxone?
Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 54,216 Copaxone users for its effectiveness, alternative drugs and more.
What is Stress and anxiety?
Stress and anxiety is found to be associated with 4,960 drugs and 5,229 conditions by eHealthMe.
Number of Copaxone and Stress and anxiety reports submitted per year:
Time on Copaxone when people have Stress and anxiety *:
Gender of people who have Stress and anxiety when taking Copaxone*:
Age of people who have Stress and anxiety when taking Copaxone *:
Common drugs people take besides Copaxone *:
Common side effects people have besides Stress and anxiety *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Copaxone and have Stress and anxiety?Check whether Stress and anxiety is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
How severe was Stress and anxiety and when was it recovered:
Expand to all the drugs that have ingredients of glatiramer acetate:
Alternative drugs to, pros and cons of Copaxone:
- Copaxone (54,216 reports)
Common Copaxone side effects:
- Fatigue (feeling of tiredness): 3,382 reports
- Drug ineffective: 3,348 reports
- Breathing difficulty: 2,754 reports
- Weakness: 2,623 reports
- Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2,596 reports
Browse all side effects of Copaxone:a b c d e f g h i j k l m n o p q r s t u v w x y z
Stress and anxiety treatments and more:
- Stress and anxiety (565,124 reports)
COVID vaccines that are related to Stress and anxiety:
- Stress and anxiety in Moderna COVID Vaccine
- Stress and anxiety in Pfizer BioNTech Covid Vaccine
- Stress and anxiety in Johnson and Johnson Covid Vaccine
Common drugs associated with Stress and anxiety:
- Prednisone: 16,002 reports
- Aspirin: 14,087 reports
- Humira: 12,166 reports
- Xanax: 10,535 reports
- Cymbalta: 10,457 reports
- Oxycontin: 10,262 reports
- Taxotere: 10,218 reports
- Truvada: 10,068 reports
- Gabapentin: 10,057 reports
- Chantix: 9,959 reports
All the drugs that are associated with Stress and anxiety:
- Stress and anxiety (4,960 drugs)
Common conditions associated with Stress and anxiety:
- Multiple sclerosis: 24,050 reports
- Depression: 23,047 reports
- Pain: 15,996 reports
All the conditions that are associated with Stress and anxiety:
- Stress and anxiety (5,229 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Valproate Sodium and Dobutrex drug interaction - now
- Sudafed 12 Hour and Oral Fibroma - a second ago
- Yasmin and Gravol drug interaction - 6 seconds ago
- Cyclosporine and Bronchitis - 10 seconds ago
- Leflunomide and Pantoprazole drug interaction - 13 seconds ago
- Tretinoin and Weakness - 13 seconds ago
- Nourianz and Chondroitin drug interaction - 16 seconds ago
- Gabitril and Diabetic Nephropathy - 16 seconds ago
- Enulose and Cardioactive Drug Level Increased - 19 seconds ago
- Pilocarpine Hydrochloride and Exjade drug interaction - 20 seconds ago